Therapeutic Uses For Aminosterol Compounds

Abstract

A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain, and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions. Appetite can be suppressed by administering an effective amount of the pharmaceutical compositions, and a diuretic effect can be produced.

1 - 13 . (canceled) 
     
     
         14 : The compound 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         15 : A pharmaceutical composition comprising the compound of  claim 14  or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. 
     
     
         16 : A method for treating obesity in a mammal, comprising administering to a mammal in need thereof an amount of the pharmaceutical composition according to  claim 15  effective to treat the obesity. 
     
     
         17 : A method for inhibiting weight gain in a mammal, comprising administering to a mammal in need thereof an amount of the pharmaceutical composition according to  claim 15  effective to inhibit the weight gain. 
     
     
         18 : The method according to  claim 16 , wherein the composition is administered in an amount from about 0.01 mg/kg of body weight/day to about 100 mg/kg of body weight/day. 
     
     
         19 : The method according to  claim 17 , wherein the composition is administered in an amount from about 0.01 mg/kg of body weight/day to about 100 mg/kg of body weight/day. 
     
     
         20 : The method according to  claim 16 , wherein the composition is administered in an amount from about 0.1 mg/kg of body weight/day to about 25 mg/kg of body weight/day. 
     
     
         21 : The method according to  claim 17 , wherein the composition is administered in an amount from about 0.1 mg/kg of body weight/day to about 25 mg/kg of body weight/day. 
     
     
         22 : The method according to  claim 16 , wherein the composition is administered orally. 
     
     
         23 : The method according to  claim 17 , wherein the composition is administered orally. 
     
     
         24 : The method according to  claim 16 , wherein the mammal is a human. 
     
     
         25 : The method according to  claim 17 , wherein the mammal is a human. 
     
     
         26 : The method according to  claim 25 , wherein the human is obese. 
     
     
         27 : The method according to  claim 25 , wherein the human is overweight. 
     
     
         28 : The method according to  claim 25 , wherein the human is of normal weight. 
     
     
         29 : The method of  claim 16  or  claim 17 , wherein administration of the composition is associated with inhibition of growth factor production in the mammal.